In Hydrocephalus, Slow Drainage May Cause Dementia
Slow clearance of an MRI tracer offers evidence of inefficient glymph transport in the brain.
ALL NEWS
6535 RESULTS
Sort By:
- Most Recent
- Most Commented
Digital Biomarkers of FTD: How to Move from Tech Tinkering to Trials?
The inaugural Holloway Summit, hosted by AFTD, focused on the development of digital health technologies to track the progression of FTD’s myriad manifestations.
In Its Latest Iteration, ADNI Broadens Diversity
ADNI4 will run from 2022 to 2027 and recruit 500 new participants, at least half of whom will be from underrepresented racial and ethnic groups.
Can Donanemab Prevent AD? Phase 3 TRAILBLAZER-ALZ3 Aims to Find Out
In collaboration with the Banner Alzheimer’s Institute, Eli Lilly will test the anti-amyloid immunotherapy in cognitively normal people with a high risk for AD based on plasma phospho-tau-217.
Introducing Alzforum Database of 137 APOE Gene Variants
Adding to our collection of APP, Presenilin, Tau, and Trem2 mutations, the new dataset curates neurologic and non-neurologic information, ranging from clinical to molecular.
Shuttle Unloads More Gantenerumab Into the Brain
New data presented at the AD/PD conference offer the first evidence that a brain-shuttle strategy can work in people; the lecanemab and aducanumab antibody programs offer small updates.
Blood Tests Go Head-to-Head in Community Cohorts
A cast of blood biomarkers for Alzheimer's has emerged from studies in research cohorts, and is now being put to the test in community cohorts. At AAIC, direct comparisons of top contenders showed that some detect amyloid and impending cognitive decline.
Could Personalizing Multimodal Interventions Give Them Oomph?
In a small pilot study, tailoring lifestyle changes to the individual boosted cognition, with an effect size three times that seen in the Finger trial.
Living in Greener Pastures May Cut Risk for Alzheimer’s, Parkinson’s
The more foliage near a person’s residence, the less likely they are to have either disease.
Cold-Shock Protein Reinvigorates Synapses
A protein that repairs synapses after hibernation falters in some models of neurodegenerative diseases.
Clinical Trials on Alzheimer's Disease (CTAD) 2022
Dare We Say Consensus Achieved: Lecanemab Slows the Disease Brexpiprazole Eases Agitation in People with AD; So Does Being in a Trial Two New Stabs at Vaccinating People Against Pathologic Tau Cognitive Tests Taken at Home Are on Par with In-Clinic Assess
After Hibernation, Bears Clear P-Tau Aggregates
Plasma p-tau climbs as bears sleep. Post-torpor, tau reverts to normal. Does neuronal metabolic activity have to do with it?
U.S. House Scolds FDA Over Aduhelm Approval
In a 45-page report, two House committees rebuked the agency for working too closely with drug sponsor Biogen.
U.S. FDA Gives Green Light to Leqembi, aka Lecanemab
Eisai’s anti-amyloid antibody got the nod via the accelerated approval pathway; the company is expected to apply for traditional approval within days.
Goodbye Antibodies, Hello AlzAntibodies: New Database Is Growing on Alzforum
A collection of antibodies against microglial proteins is starting off a new database on Alzforum.
Current Filters
No filters selected